Evidence. Protocol. Truth.

Monograph

Tadalafil — The Daily PDE5 Inhibitor, and the Longevity Story It's Been Given

07 Jul 2026

Monograph

Losartan — The Uricosuric ARB with a Marfan and TGF-β Story

Losartan (Cozaar, first FDA-approved 1995) is the prototype angiotensin II receptor blocker. It shares the class-level mechanism (selective AT1 receptor blockade), core indications (hypertension, diabetic nephropathy, heart failure, cardiovascular…

05 Jul 2026

Monograph

Fish Oil: The Right Molecule, the Wrong Dose

30 Jun 2026

Monograph

Glucosamine and Chondroitin — The Honest 2026 Read

Glucosamine and chondroitin sulfate are naturally occurring compounds found in healthy cartilage. Glucosamine is an amino sugar used by the body in glycosaminoglycan and proteoglycan synthesis; chondroitin sulfate is a long-chain sulfated…

23 Jun 2026

Monograph

Cartalax — Khavinson Short-Peptide Bioregulator for Cartilage

Cartalax (Ala-Glu-Asp, AED tripeptide) is one of approximately fifteen short-peptide bioregulators developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology beginning in the 1970s. The Khavinson…

12 Jun 2026

Protocol

Mid-Life Cognitive Optimization — A Sober Protocol

30 May 2026

Protocol

Recovery and Training Stack — A Performance Optimization Protocol

30 May 2026

Protocol

Energy and Fatigue — A Diagnostic-First Protocol

30 May 2026

Protocol

Joint and Tendon Optimization — A Layered Protocol

30 May 2026

Protocol

Anxiety and Mood — A Layered Optimization Protocol

30 May 2026

Protocol

Erectile Dysfunction — A Stepwise Optimization Protocol

30 May 2026

Monograph

Phentermine/Topiramate (Qsymia) — Second-Line Anti-Obesity in the GLP-1 Era

Qsymia is a fixed-dose combination of immediate-release phentermine (a sympathomimetic appetite suppressant) and extended-release topiramate (an anticonvulsant with appetite-reducing properties through multiple mechanisms), FDA-approved in July 2012…

30 May 2026